Free Trial

Estrella Immunopharma (ESLA) Competitors

Estrella Immunopharma logo
$2.38 +0.05 (+2.15%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$2.37 -0.01 (-0.63%)
As of 10/24/2025 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESLA vs. CRBU, VOR, TRDA, EPRX, BDTX, PYXS, GNFT, ACRS, TARA, and BHST

Should you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Caribou Biosciences (CRBU), Vor Biopharma (VOR), Entrada Therapeutics (TRDA), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), Pyxis Oncology (PYXS), GENFIT (GNFT), Aclaris Therapeutics (ACRS), Protara Therapeutics (TARA), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry.

Estrella Immunopharma vs. Its Competitors

Caribou Biosciences (NASDAQ:CRBU) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Estrella Immunopharma has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,800.93%. Caribou Biosciences' return on equity of -62.35% beat Estrella Immunopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Caribou Biosciences-1,800.93% -62.35% -49.65%
Estrella Immunopharma N/A -1,132.38%-358.54%

Caribou Biosciences currently has a consensus target price of $6.67, suggesting a potential upside of 167.74%. Estrella Immunopharma has a consensus target price of $16.00, suggesting a potential upside of 572.27%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Caribou Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Estrella Immunopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Caribou Biosciences has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

In the previous week, Caribou Biosciences and Caribou Biosciences both had 2 articles in the media. Estrella Immunopharma's average media sentiment score of 1.91 beat Caribou Biosciences' score of 1.06 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Caribou Biosciences Positive
Estrella Immunopharma Very Positive

Estrella Immunopharma has lower revenue, but higher earnings than Caribou Biosciences. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caribou Biosciences$9.99M23.21-$149.10M-$1.78-1.40
Estrella ImmunopharmaN/AN/AN/A-$0.30-7.93

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are held by institutional investors. 8.3% of Caribou Biosciences shares are held by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Caribou Biosciences beats Estrella Immunopharma on 8 of the 13 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESLA vs. The Competition

MetricEstrella ImmunopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$86.36M$3.43B$6.24B$10.67B
Dividend YieldN/A2.27%5.72%4.81%
P/E Ratio-7.9326.8131.1930.71
Price / SalesN/A451.95560.36173.93
Price / CashN/A46.1437.0861.44
Price / BookN/A10.4012.056.61
Net IncomeN/A-$52.83M$3.33B$277.10M
7 Day Performance36.00%2.10%1.93%2.56%
1 Month Performance103.42%12.33%7.77%3.77%
1 Year Performance164.44%14.14%56.40%33.01%

Estrella Immunopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESLA
Estrella Immunopharma
3.0221 of 5 stars
$2.38
+2.1%
$16.00
+572.3%
+179.7%$86.36MN/A-7.93N/ANews Coverage
Positive News
Short Interest ↓
High Trading Volume
CRBU
Caribou Biosciences
2.8315 of 5 stars
$2.44
+2.5%
$6.67
+173.2%
+36.8%$221.63M$9.12M-1.37100News Coverage
Positive News
Analyst Forecast
Gap Up
VOR
Vor Biopharma
2.5794 of 5 stars
$30.81
-4.6%
$113.83
+269.5%
N/A$221.31MN/A-0.11140Analyst Forecast
Insider Trade
TRDA
Entrada Therapeutics
3.297 of 5 stars
$6.06
+4.3%
$25.67
+323.5%
-59.4%$221.00M$79.48M-3.40110News Coverage
Analyst Forecast
EPRX
Eupraxia Pharmaceuticals
3.0054 of 5 stars
$5.87
-3.0%
$11.00
+87.4%
+119.7%$217.56MN/A-6.9129Analyst Forecast
Short Interest ↑
BDTX
Black Diamond Therapeutics
3.9722 of 5 stars
$3.76
-1.1%
$11.00
+192.6%
+29.3%$216.35MN/A16.3590Positive News
Analyst Forecast
PYXS
Pyxis Oncology
2.9742 of 5 stars
$3.23
-6.4%
$7.75
+139.9%
-7.7%$213.96M$2.82M-2.0260Analyst Forecast
GNFT
GENFIT
2.1506 of 5 stars
$4.10
-3.5%
$7.00
+70.7%
-23.3%$212.51M$76.77M0.00120
ACRS
Aclaris Therapeutics
2.5121 of 5 stars
$1.81
-5.2%
$8.71
+381.5%
+66.7%$206.91M$18.72M-1.32100Positive News
Gap Up
TARA
Protara Therapeutics
1.8534 of 5 stars
$5.36
+0.4%
$19.60
+265.7%
+155.0%$206.03MN/A-3.3130News Coverage
Analyst Forecast
BHST
BioHarvest Sciences
2.2805 of 5 stars
$12.03
-3.8%
$13.67
+13.6%
N/A$205.31M$30.19M-17.19N/ANews Coverage
Analyst Forecast
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:ESLA) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners